latest update:
[TrialBase DB]

trial summary · NCT07332507

Testing the Effect of Teclistamab on Recurrent Plasmablastic Lymphoma

Phase 1b Study of Teclistamab in Relapsed/Refractory Plasmablastic Lymphoma

Trial record from the TrialBase DB dataset, status RECRUITING, condition Recurrent Plasmablastic Lymphoma, sponsored by National Cancer Institute (NCI). Facts below are exported values from the current release, not inferred or edited prose.

registry NCT07332507phase PHASE1enrollment 30start 2027-03-26

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

This phase Ib trial tests the safety, side effects, and best dose of teclistamab in treating patients with plasmablastic lymphoma that has come back after a period of improvement (recurrent) or that has not responded to previous treatment (refractory). Teclistamab is a bispecific antibody that can bind to two different antigens at the same time. Teclistamab binds to B-cell maturation antigen (BCMA), a protein found on some B-cells and myeloma cells, and CD3 on T-cells (a type of white blood cell) and may interfere with the ability of cancer cells to grow and spread. Giving teclistamab may be safe and tolerable in treating patients with recurrent or refractory plasmablastic lymphoma.

Source record: https://clinicaltrials.gov/study/NCT07332507

Facts

registry idNCT07332507
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasePHASE1
study typeINTERVENTIONAL
lead conditionRecurrent Plasmablastic Lymphoma
sponsorNational Cancer Institute (NCI)
sponsor classNIH
enrollment30
start date2027-03-26
primary completion2027-12-31
completion2027-12-31
results postednot reported

Conditions

  • Recurrent Plasmablastic Lymphoma
  • Refractory Plasmablastic Lymphoma

Interventions

  • Biospecimen Collection
  • Computed Tomography
  • Positron Emission Tomography
  • Teclistamab

Countries

  • United States

Intervention types: DRUG, PROCEDURE

Work with this record